Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 (Ruxolitinib) in Primary and Secondary Myelofibrosis
NCT01558739Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Started May 2012; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01558739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558739.